» Articles » PMID: 2012311

Bone-cell Changes in Estrogen-induced Bone-mass Increase in Mice: Dissociation of Osteoclasts from Bone Surfaces

Overview
Journal Anat Rec
Date 1991 Feb 1
PMID 2012311
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Early studies in certain avian and mammalian species have described estrogen-associated bone-cell changes, which were based on bone cells that were neither quantified nor identified histochemically (osteoclasts). In the experiments described here, weanling female mice were given a pharmacological dose of 17 beta-estradiol benzoate (1 mg/week) for 1 and 4 weeks, and changes in osteoclasts and osteoblasts were assessed in tibial metaphyses and diaphyses. In the proximal metaphysis, the number of osteoclasts/mm surface length was significantly reduced by estrogen at 1 week (43%) and 4 weeks (64%), which was accompanied by significant increases in the number of osteoclasts in the marrow space not in contact with bone surfaces (no./mm2: 382% and 999%, respectively). These increases, along with observations of decreased osteoclast size (19%), of changes in osteoclast morphology, and of numerous acid-phosphatase-positive fragments in the marrow space, suggest that estrogen treatment causes the dissociation and disintegration, and thus decreased activity, of osteoclasts. The above changes were accompanied by more than 48% increases in the number of trabecular osteoblasts. In the diaphysis, the number of endosteal osteoclasts was significantly decreased by estrogen at 1 week (32%), but was not significantly changed at 4 weeks. These changes were attended by significant increases in the number of osteoclasts in the marrow space not in contact with bone surfaces (no./mm2: 393% at 1 week and 342% at 4 weeks). The number of endosteal osteoblasts was also increased by estrogen at 1 week (132%), and so was the size of endosteal osteoblasts (39% at 1 week and 81% at 4 weeks). Comparable results were obtained when a lower dose of 17 beta-estradiol benzoate (20 micrograms/week) was given to ovariectomized mice. The increase in bone mass and its associated cell changes following estrogen treatment were also found in athymic nude mice, suggesting that these bone/bone cell changes are independent of the thymus.

Citing Articles

Conditional Deletion of Gremlin-1 in Cathepsin K-expressing Mature Osteoclasts Altered the Skeletal Response to Calcium Depletion in Sex-Dependent Manner.

Sheng M, Rundle C, Baylink D, Lau K Calcif Tissue Int. 2025; 116(1):28.

PMID: 39789342 PMC: 11717885. DOI: 10.1007/s00223-024-01337-7.


Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation.

Kim A, Girgis C, McDonald M Curr Osteoporos Rep. 2022; 20(6):505-515.

PMID: 36201122 PMC: 9718877. DOI: 10.1007/s11914-022-00756-5.


Gsα and estrogen reveal different subsets of bone marrow adiponectin expressing osteogenic cells.

Palmisano B, Labella R, Donsante S, Remoli C, Spica E, Coletta I Bone Res. 2022; 10(1):50.

PMID: 35853852 PMC: 9296668. DOI: 10.1038/s41413-022-00220-1.


New Insights Into Osteoclast Biology.

McDonald M, Kim A, Mulholland B, Rauner M JBMR Plus. 2021; 5(9):e10539.

PMID: 34532619 PMC: 8441501. DOI: 10.1002/jbm4.10539.


Positive and negative regulators of osteoclast apoptosis.

Soysa N, Alles N Bone Rep. 2019; 11:100225.

PMID: 31720316 PMC: 6838739. DOI: 10.1016/j.bonr.2019.100225.